Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-nave prostate cancer

被引：18

作者：

Bhattasali, Onita ^{[1
]}

Chen, Leonard N. ^{[1
]}

Tong, Michael ^{[1
]}

Lei, Siyuan ^{[1
]}

Collins, Brian T. ^{[1
]}

Krishnan, Pranay ^{[2
]}

Kalhorn, Christopher ^{[3
]}

Lynch, John H. ^{[4
]}

Suy, Simeng ^{[1
]}

Dritschilo, Anatoly ^{[1
]}

Dawson, NancyA. ^{[5
]}

Collins, Sean P. ^{[1
]}

机构：

[1] Georgetown Univ Hosp, Dept Radiat Med, Washington, DC 20007 USA

[2] Georgetown Univ Hosp, Dept Radiol, 3800 Reservoir Rd NW, Washington, DC 20007 USA

[3] Georgetown Univ Med Ctr, Dept Neurosurg, Washington, DC 20007 USA

[4] Georgetown Univ Hosp, Dept Urol, Washington, DC 20007 USA

[5] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA

来源：

FRONTIERS IN ONCOLOGY | 2013年 / 3卷

关键词：

prostate cancer; SBRT; IGRT; cyberknife; oligometastases; hormone-naive;

D O I：

10.3389/fonc.2013.00293

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite advances in treatment for metastatic prostate cancer, patients eventually progress to castrate-resistant disease and ultimately succumb to their cancer. Androgen deprivation therapy (ADT) is the standard treatment for metastatic prostate cancer and has been shown to improve median time to progression and median survival time. Research suggests that castrate-resistant clones may be present early in the disease process prior to the initiation of ADT. These clones are not susceptible to ADT and may even flourish when androgen-responsive clones are depleted. Stereotactic body radiation therapy (SBRT) is a safe and efficacious method of treating clinically localized prostate cancer and metastases. In patients with a limited number of metastatic sites, SBRT may have a role in eliminating castrate-resistant clones and possibly delaying progression to castrate-resistant disease.

引用

页数：7

共 73 条

[1]

Ahmed KA, 2012, FRONT ONCOL, V2, DOI [10.3389/fonc.2012.00215, 10.3389/fonc.2012.00172]

[2] Adaptation and clonal selection models of castration-resistant prostate cancer: Current perspective [J].

Ahmed, Muhammed ;

Li, Long-Cheng .

INTERNATIONAL JOURNAL OF UROLOGY, 2013, 20 (04) :362-371

[3] Health-related quality of life among patients with metastatic prostate cancer [J].

Albertsen, PC ;

Aaronson, NK ;

Muller, MJ ;

Keller, SD ;

Ware, JE .

UROLOGY, 1997, 49 (02) :207-216

[4] Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases [J].

Alongi, Filippo ;

Arcangeli, Stefano ;

Filippi, Andrea Riccardo ;

Ricardi, Umberto ;

Scorsetti, Marta .

ONCOLOGIST, 2012, 17 (08) :1100-1107

[5] Stereotactic body radiation therapy: The report of AAPM Task Group 101 [J].

Benedict, Stanley H. ;

Yenice, Kamil M. ;

Followill, David ;

Galvin, James M. ;

Hinson, William ;

Kavanagh, Brian ;

Keall, Paul ;

Lovelock, Michael ;

Meeks, Sanford ;

Papiez, Lech ;

Purdie, Thomas ;

Sadagopan, Ramaswamy ;

Schell, Michael C. ;

Salter, Bill ;

Schlesinger, David J. ;

Shiu, Almon S. ;

Solberg, Timothy ;

Song, Danny Y. ;

Stieber, Volker ;

Timmerman, Robert ;

Tome, Wolfgang A. ;

Verellen, Dirk ;

Wang, Lu ;

Yin, Fang-Fang .

MEDICAL PHYSICS, 2010, 37 (08) :4078-4101

[6] Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy [J].

Berkovic, Patrick ;

De Meerleer, Gert ;

Delrue, Louke ;

Lambert, Bieke ;

Fonteyne, Valerie ;

Lumen, Nicolaas ;

Decaestecker, Karel ;

Villeirs, Geert ;

Vuye, Philippe ;

Ost, Piet .

CLINICAL GENITOURINARY CANCER, 2013, 11 (01) :27-32

[7] Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer [J].

Berry, W ;

Dakhil, S ;

Modiano, M ;

Gregurich, M ;

Asmar, L .

JOURNAL OF UROLOGY, 2002, 168 (06) :2439-2443

[8] Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study [J].

Berthold, Dominik R. ;

Pond, Gregory R. ;

Soban, Freidele ;

de Wit, Ronald ;

Eisenberger, Mario ;

Tannock, Ian F. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :242-245

[9] Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy [J].

Cai, Changmeng ;

Balk, Steven P. .

[10] Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience [J].

Chen, Leonard N. ;

Suy, Simeng ;

Uhm, Sunghae ;

Oermann, Eric K. ;

Ju, Andrew W. ;

Chen, Viola ;

Hanscom, Heather N. ;

Laing, Sarah ;

Kim, Joy S. ;

Lei, Siyuan ;

Batipps, Gerald P. ;

Kowalczyk, Keith ;

Bandi, Gaurav ;

Pahira, John ;

McGeagh, Kevin G. ;

Collins, Brian T. ;

Krishnan, Pranay ;

Dawson, Nancy A. ;

Taylor, Kathryn L. ;

Dritschilo, Anatoly ;

Lynch, John H. ;

Collins, Sean P. .

RADIATION ONCOLOGY, 2013, 8

← 1 2 3 4 5 6 7 8 →